Nessan Bermingham is the CEO, president, and founder of Intellia Therapeutics, a leading gene-editing company. Most recently, Nessan was a venture partner at Atlas Venture and was previously the CEO of Tal Medical, a medical device company spun out of Harvard Medical School.
Nessan has more than 15 years of experience in life sciences investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. He was a Howard Hughes Associate Fellow at Baylor College of Medicine, earned a Ph.D. in molecular biology from Imperial College London, and received his B.S. from Queen’s University Belfast. His leadership and business successes have been recognized recently as Intellia was named a Top 10 Biotech Startup in 2014, and a Fierce 15 Top Biotech Company.
Nessan was born in Cork to parents who came originally from Limerick, and he credits his success to growing up in Ireland: “The education system, core personal and family values in addition to instilling the sense of adventure and willingness to leave home were central in molding me into who I am today.”